Welcome to EGB Advisors

Essentially "Drug Hunting" to us is an arbitrage of geography or time to create new value from existing molecules, with new intellectual property and new important benefits to patients.

2000-2004

EGB was founded on our in-licensing of clinical-stage small molecule therapeutics ("drug hunting") practice for clients such as CoTherix (Actelion) and ChemGenex (Cephalon/Teva). Historically we have also worked on behalf of technology transfer offices such as M.D. Anderson Cancer Center and for the Kauffman Foundation in its efforts to improve commercialization of technology.

2004-Present

In 2004, EGB began to develop our own portfolio companies after reviewing over 1,000 technologies. Only two met our proprietary criteria, and we formed Inverseon, Inc. and Urigen Pharmaceuticals, Inc.

Inverseon, Inc. is poised to transform important pulmonary diseases. In 2010, the Chairman of an FDA review panel said that Inverseon's approach has the potential to replace the best selling class of pulmonary drugs worldwide. In 2011, Inverseon was commended for our potential to advance the treatment of COPD by Medical Futures in the UK. Dr. Garner founded Inverseon in 2004 with Dr. Franklin and served as principal investigator on Inverseon’s STTR grants while raising private capital.

The paradigm of local treatment of IC/PBS was industrialized by Urigen through incubation at EGB.Urigen completed a multi-center double-blind, placebo-controlled clinical trial of URG101 for Interstitial Cystitis/Painful Bladder Syndrome (IC/ PBS) with statistical significance on the primary pain endpoint and all secondary measures of response. Dr. Garner founded Urigen and took it public in 2007.

In 2010 we founded DelMar Pharmaceuticals, Inc. of Vancouver, Canada (www.delmarpharma.com) to reposition a drug approved in China after modern biologics fail. DelMar has opened a clinical trial of VAL-083 in Glioblastoma (primary brain tumors) after Avastin®. DelMar follows the business model of ChemGenex, founded by Dr. Brown. ChemGenex was acquired in 2011 for approximately $350M including European rights.